{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:59:58Z","timestamp":1784872798684,"version":"3.55.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02145","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T06:10:56Z","timestamp":1537337456000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Durable Clinical Responses and Long-Term Follow-Up of Stage III\u2013IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study\u2014A Brief Research Report"],"prefix":"10.3389","volume":"9","author":[{"given":"Julie Westerlin","family":"Kjeldsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Zeeberg","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Engell-Noerregaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Mellemgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non\u2013small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"75407","DOI":"10.18632\/oncotarget.12249","article-title":"Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment","volume":"7","author":"Schafer","year":"2016","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1158\/1078-0432.CCR-10-2805","article-title":"Prognostic immune markers in non\u2013small cell lung cancer","volume":"17","author":"Suzuki","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1182\/blood-2010-06-288498","article-title":"Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators","volume":"117","author":"S\u00f8rensen","year":"2011","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1078-0432.CCR-13-1560","article-title":"Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase","volume":"20","author":"Iversen","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"P428","DOI":"10.1186\/2051-1426-3-S2-P428","article-title":"Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines","volume":"3","author":"Ascarateil","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","article-title":"Chemotherapy and survival benefit in elderly patients with advanced non\u2013small-cell lung cancer","volume":"28","author":"Davidoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejcts.2003.09.015","article-title":"Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study","volume":"25","author":"Sienel","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/CJI.0b013e31818fe167","article-title":"Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer","volume":"32","author":"Neninger","year":"2009","journal-title":"J Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-11-1385","article-title":"Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial","volume":"17","author":"Brunsvig","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1158\/1078-0432.CCR-13-1674","article-title":"A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non\u2013small cell lung cancer patients","volume":"20","author":"Alfonso","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Eng J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9014","DOI":"10.1200\/JCO.2017.35.15_suppl.9014","article-title":"Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","volume":"35","author":"Gangadhar","year":"2017","journal-title":"J Clin Oncol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T06:10:57Z","timestamp":1537337457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2018.02145"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02145","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"article-number":"2145"}}